Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561749 | 0.89 | MEN1 (0.42) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3564887 | 0.89 | MEN1 (0.42) | SMN1; SMN2MEN1KMT2AATMFPR1 | |
| SCHEMBL29881718 | 0.89 | MEN1 (0.42) | SMN1; SMN2MEN1KMT2AATMFPR1 | |
| SCHEMBL3566327 | 0.83 | HCRTR1 (0.43) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3564261 | 0.82 | MEN1 (0.42) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3564525 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3566382 | 0.80 | MEN1 (0.41) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3560978 | 0.79 | HCRTR1 (0.45) | SMN1; SMN2MEN1KMT2AATMTSHR | |
| SCHEMBL3565825 | 0.78 | KMT2A (0.41) | SMN1; SMN2MEN1KMT2AATMKDM4E | |
| SCHEMBL29880962 | 0.78 | KMT2A (0.41) | SMN1; SMN2MEN1KMT2AATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | claimed |
| EP-3043865-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | INST NAT SANTE RECH MED (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3711762-A1 | A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-09-23 | — | — | EP | disclosed |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-11 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-08-04 | — | — | US | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | SMN1; SMN2 4791/4885MEN1 4283/4885KMT2A 3963/4885 |
| US-20160220586-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, NR1H3, FXR2 | SMN1; SMN2 4778/4885MEN1 4150/4885KMT2A 4178/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | SMN1; SMN2 4754/4885MEN1 3627/4885KMT2A 3552/4885 |
| US-10071108-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection | NR1H4, FXR2, FXR1 | SMN1; SMN2 4791/4885MEN1 4283/4885KMT2A 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.